Q3 2018 EPS Estimates for FibroGen, Inc (FGEN) Increased by Analyst
FibroGen, Inc (NASDAQ:FGEN) – Investment analysts at William Blair lifted their Q3 2018 earnings per share estimates for FibroGen in a research note issued to investors on Thursday. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will earn $1.00 per share for the quarter, up from their previous forecast of $0.86. William Blair has a “Outperform” rating on the stock.
A number of other equities research analysts also recently issued reports on the stock. Goldman Sachs Group, Inc. (The) downgraded shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective on the stock. in a research note on Friday, July 21st. BidaskClub lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Stifel Nicolaus boosted their price target on shares of FibroGen from $38.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, August 8th. Jefferies Group LLC restated a “buy” rating and set a $75.00 price target on shares of FibroGen in a research note on Tuesday, August 8th. Finally, Citigroup Inc. lifted their price objective on shares of FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a report on Tuesday, August 8th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $65.67.
Shares of FibroGen (FGEN) traded down $1.13 during mid-day trading on Friday, reaching $47.12. 754,500 shares of the company’s stock were exchanged, compared to its average volume of 626,675. The company has a quick ratio of 6.21, a current ratio of 10.83 and a debt-to-equity ratio of 0.16. FibroGen has a 12-month low of $19.25 and a 12-month high of $60.15.
In related news, insider K Peony Yu sold 15,000 shares of the stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $60.00, for a total value of $900,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kalevi Kurkijarvi sold 2,000 shares of the stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $40.74, for a total value of $81,480.00. Following the completion of the sale, the director now directly owns 30,000 shares of the company’s stock, valued at approximately $1,222,200. The disclosure for this sale can be found here. In the last three months, insiders have sold 428,118 shares of company stock worth $22,355,896. Corporate insiders own 14.90% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the business. New York State Common Retirement Fund grew its stake in shares of FibroGen by 24.0% in the second quarter. New York State Common Retirement Fund now owns 67,700 shares of the biopharmaceutical company’s stock valued at $2,187,000 after buying an additional 13,099 shares in the last quarter. FMR LLC lifted its holdings in FibroGen by 96.9% during the 2nd quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock worth $107,753,000 after buying an additional 1,641,423 shares during the last quarter. Prudential Financial Inc. lifted its holdings in FibroGen by 9.6% during the 2nd quarter. Prudential Financial Inc. now owns 448,780 shares of the biopharmaceutical company’s stock worth $14,496,000 after buying an additional 39,430 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of FibroGen by 0.4% during the first quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock worth $3,354,000 after purchasing an additional 504 shares in the last quarter. Finally, Citigroup Inc. increased its position in shares of FibroGen by 37.3% during the second quarter. Citigroup Inc. now owns 40,046 shares of the biopharmaceutical company’s stock worth $1,294,000 after purchasing an additional 10,876 shares in the last quarter. 47.47% of the stock is owned by institutional investors.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.